Dec 14, 2011 10:33 CET The US continues to dominate; most venture capital goes to drug discovery platforms and the most successful companies in need of venture capital are those who most clearly fit in to investors' strategy. Despite a leading R&D position, Swedish life science companies must improve international relations to succeed in attracting investments. This emerged in a new report on corporate venture capital.